A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a single-arm, multi-center, open-label, phase 2 study to evaluate the efficacy and safety of ICP-248 in subjects with relapsed or refractory mantle cell lymphoma.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Potwierdzony chłoniak z komórek płaszcza z mutacją Cyclin D1 lub translokacją t(11;14)
- •Wcześniejsze niepowodzenie co najmniej jednej linii terapii zawierającej anty-CD20
- •Wcześniejsze niepowodzenie co najmniej jednej linii terapii zawierającej inhibitor BTK
- •Brak odpowiedzi na ostatnią otrzymaną terapię
- •Co najmniej jeden zmierzalny guz widoczny w badaniach obrazowych
- •Ogólny stan zdrowia pozwalający na uczestnictwo (skala ECOG 0-2)
✗ Disqualifies
- •Historia chłoniaka w ośrodkowym układzie nerwowym
- •Wcześniejsze leczenie inhibitorami BCL-2 (np. venetoclax)
- •Przeszczep autologicznych komórek macierzystych lub terapia komórkowa w ciągu 3 miesięcy przed badaniem
- •Przeszczep allogenniczny szpiku kostnego w przeszłości
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 23, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (29)
The First Affiliated Hospital of Anhui Medical University
Hefei, China
Peking University Third Hospital
Beijing, China
West China Hospital of Sichuan University
Chengdu, China
The First Affiliated Hospital of Chongqing Medical University
Chongqing, China
Chongqing University Cancer Hospital
Chongqing, China
Fujian Medical University Union Hospital
Fuzhou, China
Sun Yat-sen University Cancer Center
Guangzhou, China
Guangdong Provincial People's Hospital
Guangzhou, China
Guangxi Medical University Cancer Hospital
Nanning, China
Henan Cancer Hospital
Zhengzhou, China
Henan Provincial People's Hospital
Zhengzhou, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, China
Hunan Cancer Hospital
Changsha, China
The First Affiliated Hospital of University of South China
Hengyang, China
Jiangsu Province Hospital
Nanjing, China
The First Affiliated Hospital of Nanchang University
Nanchang, China
The First Hospital of Jilin University
Changchun, China
Qilu Hospital of Shandong University
Jinan, China
Shandong Provincial Hospital Affiliated to Shandong First Medical University
Jinan, China
Shandong Cancer Hospital
Jinan, China
The Affiliated Hospital of Qingdao University
Qingdao, China
Fudan University Shanghai Cancer Center
Shanghai, China
The Second Affiliated Hospital of Xi'an Jiaotong University
Xian, China
Sichuan Provincial People's Hospital
Chengdu, China
The Second People's Hospital of Yibin
Yibin, China
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, China
The Affiliated Cancer Hospital of Xinjiang Medical University
Xinjiang, China
The First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, China
Trial contact
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/24/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.